NCT06949124 2025-09-10
A Phase 1 Clinical Study to Evaluate the Effects of SHR7280 on the Pharmacokinetics of Midazolam, S-warfarin, Omeprazole, Digoxin, and Rosuvastatin in Healthy Subjects
Jiangsu HengRui Medicine Co., Ltd.
Phase 1 Completed
Clinical Trials
17 trialsNCT06969664 2025-08-19
A Trial of SHR7280 in Healthy Subjects
Jiangsu HengRui Medicine Co., Ltd.
Phase 1 Completed
NCT05868057 2023-12-08
A Clinical Study Evaluating the Relative Bioavailability of SHR7280 Dry Suspension and Tablets
Jiangsu HengRui Medicine Co., Ltd.
Phase 1 Completed
NCT05986266 2023-10-17
Evaluating Efficacy of Intravenous Carbetocin Versus Intramyometrial Injection of Adrenaline in Reducing Blood Loss
Egymedicalpedia
Phase 1 Completed
NCT04177693 2023-06-05
Pharmacokinetics and Hepatic Safety of EGCG
Yale University
Phase 1 Completed
NCT02620748 2022-10-13
TA
George Washington University
Phase 1 Completed
NCT03342859 2021-01-06
Mode of Action Study of Vilaprisan and Ulipristal Acetate in Patients With Uterine Fibroids for Whom Surgery is Planned
Bayer
Phase 1 Terminated
NCT03411980 2019-12-03
Pharmacokinetics and Safety of Vilaprisan in Renal Impairment
Bayer
Phase 1 Completed
NCT02889848 2019-07-10
Safety and Tolerability of Collagenase Clostridium Histolyticum (EN3835) to Treat Uterine Leiomyoma (Fibroids)
Advance Biofactures Corporation
Phase 1 Completed
NCT03092999 2017-08-18
Effect of Hepatic Impairment on the Pharmacokinetics, Safety and Tolerability of BAY1002670 (Vilaprisan)
Bayer
Phase 1 Completed
NCT00579475 2015-05-25
The Effect of Mifepristone on Uterine Fibroids and Breast Tissue
Karolinska Institutet
Phase 1 Completed
NCT02283502 2014-11-05
MRgHIFU
Chang Gung Memorial Hospital
Phase 1 Unknown
NCT00945360 2012-07-13
Aromatase Inhibitors for Treatment of Uterine Leiomyomas
American University of Beirut Medical Center
Phase 1 Withdrawn
NCT00361036 2011-04-18
Comparison Study in the Treatment of Uterine Fibroids Uterine Fibroid Embolization Using BeadBlockâ„¢ Embolic Agent
Worthington-Kirsch, Robert L., M.D.
Phase 1 Completed
NCT00444704 2009-07-10
Study of Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of PRA-027 Administered to Healthy Japanese Females
Wyeth is now a wholly owned subsidiary of Pfizer
Phase 1 Completed
NCT00574418 2009-01-05
Far Infrared Radiation Treatment for Uterine Fibroids
GAAD Medical Research Institute Inc.
Phase 1 Unknown
NCT00427544 2007-12-05
Study of the Safety, Tolerability, and PK of PRA-027 Administered to Women of Nonchildbearing Potential
Wyeth is now a wholly owned subsidiary of Pfizer
Phase 1 Completed